|View printer-friendly version|
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170405005195/en/
The collaboration announced today expands upon the long-standing relationship between Nimbus and Charles River to work on targets of critical importance. Nimbus, a biotechnology company applying deep computational chemistry expertise throughout drug discovery and development, collaborates closely with Charles River as part of its unique outsourcing model to design breakthrough medicines.
The combined team will advance programs through discovery and preclinical development, taking advantage of Charles River’s capabilities from initial hit identification through all aspects of discovery optimization, including medicinal chemistry and pharmacology, and ultimately, into safety testing and IND submission. Under the terms of the agreement, Charles River is eligible to receive potential milestone payments from Nimbus for certain undisclosed program advancements.
“We expect that our portfolio of discovery and safety assessment
expertise, together with Nimbus’ impressive track record in using
computational chemistry to accelerate drug discovery, will result in
additional speed and scale to their future pipeline,” said
About Nimbus Therapeutics
Nimbus Therapeutics is a biotechnology company headquartered in
About Charles River
Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.
Ten Bridge Communications
Dan Quinn, 781-475-7974
Amy Cianciaruso, 781-222-6168
Corporate Vice President, Public Relations
Susan E. Hardy, 781-222-6190
Corporate Vice President, Investor Relations